Literature DB >> 21641394

Autoreactive cytotoxic T lymphocytes acquire higher expression of cytotoxic effector markers in the islets of NOD mice after priming in pancreatic lymph nodes.

Kate L Graham1, Balasubramanian Krishnamurthy, Stacey Fynch, Zia U Mollah, Robyn Slattery, Pere Santamaria, Thomas W Kay, Helen E Thomas.   

Abstract

Cytotoxic T lymphocytes (CTLs) that cause type 1 diabetes are activated in draining lymph nodes and become concentrated as fully active CTLs in inflamed pancreatic islets. It is unclear whether CTL function is driven by signals received in the lymph node or also in the inflamed tissue. We studied whether the development of cytotoxicity requires further activation in islets. Autoreactive CTLs found in the islets of diabetes-prone NOD mice had acquired much higher expression of the cytotoxic effector markers granzyme B, interferon γ, and CD107a than had those in the pancreatic lymph node (PLN). Increased expression seemed to result from stimulation in the islet itself. T cells held up from migrating from the PLN by administration of the sphingosine-1-phosphate agonist FTY720 did not increase expression of cytotoxic molecules in the PLN. Stimulation did not require antigen presentation or cytokine secretion by the target β cells because it was not affected by the absence of class I major histocompatibility complex expression or by the overexpression of suppressor of cytokine signaling-1. Activation of CD40-expressing cells stimulated increased CTL function and β-cell destruction, suggesting that signals derived from CD40-expressing cells promote the acquisition of cytotoxicity in the islet environment. These data provide in vivo evidence that stimulation of cytotoxic effector molecule expression occurs in inflamed islets and is independent of β cells.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641394      PMCID: PMC3124028          DOI: 10.1016/j.ajpath.2011.02.015

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes.

Authors:  Yi-Guang Chen; Caroline-Morgane Choisy-Rossi; Thomas M Holl; Harold D Chapman; Gurdyal S Besra; Steven A Porcelli; Daniel J Shaffer; Derry Roopenian; S Brian Wilson; David V Serreze
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

2.  In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8+ T cell inflammation.

Authors:  Jinguo Wang; Sue Tsai; Afshin Shameli; Jun Yamanouchi; Gonnie Alkemade; Pere Santamaria
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

3.  Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways.

Authors:  Nadine L Dudek; Helen E Thomas; Lina Mariana; Robyn M Sutherland; Janette Allison; Eugene Estella; Eveline Angstetra; Joseph A Trapani; Pere Santamaria; Andrew M Lew; Thomas W H Kay
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

4.  Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP.

Authors:  Balasubramanian Krishnamurthy; Nadine L Dudek; Mark D McKenzie; Anthony W Purcell; Andrew G Brooks; Shane Gellert; Peter G Colman; Leonard C Harrison; Andrew M Lew; Helen E Thomas; Thomas W H Kay
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

5.  Effector CD8+ T cells recovered from an influenza pneumonia differentiate to a state of focused gene expression.

Authors:  Dana R Marshall; Elvia Olivas; Samita Andreansky; Nicole L La Gruta; Geoff A Neale; Astrid Gutierrez; David G Wichlan; Suzette Wingo; Cheng Cheng; Peter C Doherty; Stephen J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-14       Impact factor: 11.205

6.  IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation.

Authors:  Michelle L Janas; Penny Groves; Norbert Kienzle; Anne Kelso
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

7.  IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes.

Authors:  H E Thomas; J L Parker; R D Schreiber; T W Kay
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

8.  Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.

Authors:  Cristina Penaranda; Qizhi Tang; Nancy H Ruddle; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

9.  T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event.

Authors:  Greig P Lennon; Maria Bettini; Amanda R Burton; Erica Vincent; Paula Y Arnold; Pere Santamaria; Dario A A Vignali
Journal:  Immunity       Date:  2009-10-08       Impact factor: 31.745

10.  Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes.

Authors:  P Höglund; J Mintern; C Waltzinger; W Heath; C Benoist; D Mathis
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

View more
  19 in total

1.  Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes.

Authors:  Lorraine Yeo; Alyssa Woodwyk; Sanjana Sood; Anna Lorenc; Martin Eichmann; Irma Pujol-Autonell; Rosella Melchiotti; Ania Skowera; Efthymios Fidanis; Garry M Dolton; Katie Tungatt; Andrew K Sewell; Susanne Heck; Alka Saxena; Craig A Beam; Mark Peakman
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

Review 2.  Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2018-08-30       Impact factor: 4.810

Review 3.  Pathogenic mechanisms in type 1 diabetes: the islet is both target and driver of disease.

Authors:  Kate L Graham; Robyn M Sutherland; Stuart I Mannering; Yuxing Zhao; Jonathan Chee; Balasubramanian Krishnamurthy; Helen E Thomas; Andrew M Lew; Thomas W H Kay
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 4.  Mechanisms of diabetic autoimmunity: II--Is diabetes a central or peripheral disorder of effector and regulatory cells?

Authors:  Nadir Askenasy
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

5.  An evolving autoimmune microenvironment regulates the quality of effector T cell restimulation and function.

Authors:  Rachel S Friedman; Robin S Lindsay; Jason K Lilly; Vinh Nguyen; Caitlin M Sorensen; Jordan Jacobelli; Matthew F Krummel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-10       Impact factor: 11.205

6.  Self-Renewing Islet TCF1+ CD8 T Cells Undergo IL-27-Controlled Differentiation to Become TCF1- Terminal Effectors during the Progression of Type 1 Diabetes.

Authors:  Ashley E Ciecko; David M Schauder; Bardees Foda; Galina Petrova; Moujtaba Y Kasmani; Robert Burns; Chien-Wei Lin; William R Drobyski; Weiguo Cui; Yi-Guang Chen
Journal:  J Immunol       Date:  2021-09-10       Impact factor: 5.426

Review 7.  Mechanisms of autoimmunity in the non-obese diabetic mouse: effector/regulatory cell equilibrium during peak inflammation.

Authors:  Nadir Askenasy
Journal:  Immunology       Date:  2016-02-08       Impact factor: 7.397

Review 8.  Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes.

Authors:  Ayelet Kaminitz; Shifra Ash; Nadir Askenasy
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 9.  Mechanisms of diabetic autoimmunity: I--the inductive interface between islets and the immune system at onset of inflammation.

Authors:  Nadir Askenasy
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

10.  Granzyme B is dispensable in the development of diabetes in non-obese diabetic mice.

Authors:  Zia U Mollah; Kate L Graham; Balasubramanian Krishnamurthy; Prerak Trivedi; Thomas C Brodnicki; Joseph A Trapani; Thomas W Kay; Helen E Thomas
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.